Yes. As of October 2026, nurse practitioners can prescribe controlled substances when their state grants that authority and they hold a Drug Enforcement Administration (DEA) registration for the state where they practice. State law sets the limits, and they differ sharply: Kentucky limits most APRN Schedule II prescriptions to a 72-hour supply. For telehealth, federal flexibilities that waive the in-person visit run through December 31, 2026.
How do nurse practitioners get authority to prescribe controlled substances?
Prescribing a controlled substance takes up to three layers of permission, and an NP needs every layer that applies in the state where the patient is treated. Federal rules give NPs their own category: a mid-level practitioner is a practitioner other than a physician, dentist, veterinarian or podiatrist whom the jurisdiction permits to dispense controlled substances, and the definition names nurse practitioners, nurse midwives, nurse anesthetists and clinical nurse specialists as examples (21 CFR 1300.01).
The federal registration depends on the state layer. In a March 2020 letter announcing a temporary COVID-19 emergency exception, DEA restated the baseline rule: it "may only register a person to dispense a controlled substance if that person is permitted to do so by the jurisdiction in which he or she practices," and its regulations require "a separate DEA registration in each state in which he or she dispenses a controlled substance," where dispensing includes prescribing (DEA letter DEA067, March 25, 2020).
| Layer | Who grants it | What it decides |
|---|---|---|
| State prescriptive authority | The state legislature and the board of nursing (or a joint board) | Whether you may prescribe controlled substances, which schedules, supply limits, and any physician collaboration |
| State controlled substance registration | A state agency, in states that have one; Missouri is an example | A separate state credential to prescribe or dispense controlled substances |
| Federal DEA registration | DEA Diversion Control Division | Your DEA number for that state, for the schedules you are authorized to prescribe |
Missouri shows the middle layer: no person may "dispense or prescribe any controlled substance" without "having first obtained a registration issued by the department of health and senior services" (RSMo 195.030, effective January 1, 2017). DEA's fee schedule lists $888 for a three-year practitioner registration, the same for renewal (21 CFR 1301.13).
A state's practice authority category does not settle the question alone; in the examples below, the limits sit in specific statutory provisions. The state practice authority reference and the full practice authority guide explain the categories.
What do the drug schedules mean for NP prescribing?
A drug's federal schedule, set in 21 CFR part 1308, determines which rules apply. Your DEA registration lists the schedules you may prescribe, and your state may narrow them.
| Schedule | Examples named in the regulation | Federal citation |
|---|---|---|
| II (stimulants) | Amphetamine, lisdexamfetamine, methylphenidate, methamphetamine | 21 CFR 1308.12(d) |
| II (opioids) | Oxycodone, hydrocodone, fentanyl | 21 CFR 1308.12(b) and (c) |
| III | Buprenorphine | 21 CFR 1308.13(e) |
| IV | Alprazolam, clonazepam, lorazepam, zolpidem | 21 CFR 1308.14(c) |
This is why "can nurse practitioners prescribe Adderall" has no single national answer. The Adderall label states that it "contains amphetamine, a Schedule II controlled substance" (DailyMed, label updated May 29, 2024), and each state sets its own Schedule II rules for NPs.
How do state limits on NP controlled substance prescribing differ?
State limits differ enough that the only reliable answer is your own state's law. Three examples, each read at the state's official code site on October 6, 2026:
| State | What the statute says about NP controlled substance prescribing | Source |
|---|---|---|
| Florida | The APRN formulary must limit Schedule II prescriptions to a 7-day supply, except psychiatric medications prescribed by psychiatric nurses; psychiatric mental health controlled substances for patients under 18 are restricted to APRNs who are psychiatric nurses | Fla. Stat. 464.012(6)(a), 2026 Florida Statutes |
| Kentucky | APRNs may prescribe but not dispense Schedules II to V. Schedule II is limited to a 72-hour supply without refill, except hydrocodone combination products (30 days without refill); Schedule III to 30 days without refill; Schedules IV and V to six months including refills | KRS 314.011(8), effective June 27, 2025 |
| Missouri | A collaborative practice arrangement may delegate Schedules III, IV and V and Schedule II hydrocodone. Schedule III narcotic and Schedule II hydrocodone prescriptions are limited to a 120-hour supply without refill; a separate provision covers Schedule II for hospice patients | RSMo 334.104, effective August 28, 2023 |
Kentucky's nursing regulation also requires an APRN with controlled substance prescriptive authority to obtain a DEA registration, report the Kentucky DEA number to the board within 30 days, and register with the state prescription drug monitoring program (PDMP) before prescribing controlled substances (201 KAR 20:057, Section 6(4), effective February 13, 2025). These are examples only: check your state with the licensure checker, the state's guide (for example Florida, Kentucky or Missouri), and the board itself.
Can a psychiatric nurse practitioner prescribe medication?
Yes. A psychiatric mental health nurse practitioner (PMHNP) prescribes under the same layers as any NP. Non-controlled psychiatric medications follow the state's general prescriptive authority; ADHD stimulants and benzodiazepines are controlled, so the schedule rules apply. Some statutes add PMHNP-specific rules:
- Florida exempts psychiatric medications prescribed by psychiatric nurses (as defined in Fla. Stat. 394.455) from the 7-day Schedule II limit, and reserves psychiatric controlled substances for patients under 18 to those nurses (Fla. Stat. 464.012(6)(a)).
- Kentucky allows a 30-day psychostimulant supply only for an APRN "certified in psychiatric-mental health nursing" who provides services in a health facility under KRS Chapter 216B or a regional services program under KRS Chapter 210 (KRS 314.011(8)(a)3). Otherwise the 72-hour Schedule II limit applies.
For a PMHNP weighing an offer, the same certification can carry different stimulant rules by state and, in Kentucky, by setting. Read the statute before accepting a panel built around ADHD care. Open roles are on the psychiatric mental health jobs page.
Can nurse practitioners prescribe buprenorphine?
Yes, if state law allows it and the NP's DEA registration covers Schedule III. DEA told registrants that Congress eliminated the DATA-Waiver program (the X-waiver) on December 29, 2022, that "all prescriptions for buprenorphine only require a standard DEA registration number," that patient caps are gone, and that the change "does not impact existing state laws or regulations" (DEA letter, January 12, 2023). Missouri, for example, allows an APRN up to a 30-day buprenorphine supply without refill for medication-assisted treatment (RSMo 334.104).
The same law, the Consolidated Appropriations Act, 2023, created a training requirement for every DEA-registered practitioner except those who are solely veterinarians (DEA letter, March 27, 2023):
- It is a one-time, eight-hour training on treating and managing patients with opioid or other substance use disorders.
- You affirm it by checking a box on your first DEA registration submission, initial or renewal, on or after June 27, 2023; later renewals do not repeat it.
- You are deemed to have met it if you graduated in good standing from a US advanced practice nursing school within five years of June 27, 2023 and your curriculum included at least eight hours on these topics.
- Otherwise, eight hours from listed providers count, including the American Association of Nurse Practitioners (AANP) and the American Nurses Credentialing Center (ANCC). Hours may be cumulative, and past DATA-waiver training counts.
What are the DEA telehealth prescribing rules for 2026?
Through December 31, 2026, a DEA-registered practitioner may prescribe Schedule II to V controlled substances by telemedicine without first seeing the patient in person, under a temporary federal rule. The baseline is the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (the Ryan Haight Act), under which a practitioner, "subject to certain exceptions," may prescribe remotely "only after conducting at least one in-person medical evaluation." DEA and HHS published the Fourth Temporary Extension on December 31, 2025, "effective January 1, 2026 through December 31, 2026" (90 FR 61301).
Under that rule, the prescription must be for a legitimate medical purpose, issued through an interactive telecommunications system, within the schedules your registration authorizes, and consistent with 21 CFR part 1306. Separately, DEA guidance says practitioners "generally must be registered with DEA in a patient's state" to prescribe to that patient by telemedicine, with exceptions (DEA guidance, July 28, 2020).
According to the fourth extension, two permanent final rules took effect on December 31, 2025:
- Buprenorphine by telemedicine. A practitioner may prescribe Schedule III to V medications approved for opioid use disorder by telemedicine, including audio-only, for an initial six-month supply after reviewing PDMP data for the state where the patient is located. After that, prescribing requires an in-person evaluation or another form of telemedicine the law allows (90 FR 6504).
- VA continuity of care. VA practitioners acting within their VA employment may prescribe by telemedicine when another VA practitioner has previously evaluated the patient in person (90 FR 6523).
The longer-term rule is pending. DEA proposed "Special Registrations for Telemedicine and Limited State Telemedicine Registrations" on January 17, 2025 (90 FR 6541): a registration for Schedules III to V; an advanced registration for Schedules II to V limited to listed specialties, including mid-level practitioners board certified in treating psychiatric or psychological disorders; a platform registration; and state telemedicine registrations for each state where patients are located. A final rule (RIN 1117-AB40) reached the White House Office of Information and Regulatory Affairs (OIRA) on August 25, 2026 and was still on OIRA's list of rules under review dated October 5, 2026 (Reginfo.gov). Its text is not public and may differ from the proposal.
| Possible path after December 31, 2026 | What it would mean |
|---|---|
| Another temporary extension | The current flexibilities continue for the period the extension sets |
| A final special registration rule | Telemedicine prescribing without an in-person visit runs through the new registration, on the final text's terms |
| Neither takes effect | The Ryan Haight in-person requirement applies again, subject to its exceptions, including the buprenorphine and VA rules |
As of October 6, 2026, the Federal Register showed no fifth extension and no final special registration rule. No path has been announced, and this article does not predict one.
What PMHNPs, telehealth NPs and employers can do now
The useful work is the same under all three paths: know where your patients are, hold the right registrations, and plan for in-person evaluations.
- List every state where your patients are located and confirm you hold an NP license and prescriptive authority in each.
- Match DEA registrations to those states, for the schedules you prescribe, plus any state controlled substance registration the state requires, as Missouri does.
- Confirm your one-time training affirmation is done, or that you qualify as a recent graduate.
- Get PDMP access in each patient state; the buprenorphine telemedicine rule requires a PDMP review before prescribing under it.
- Ask a telehealth employer, in writing, how it will handle January 1, 2027 under each path: in-person evaluation logistics, which patients would need one, and who pays for added registrations. The remote and telehealth NP jobs guide lists other questions.
- Put registrations on your credentialing calendar. DEA registrations run three years; the credentialing checklist shows where they fit.
Employers hiring prescribers across states can list the registrations a role requires when they post a job. NPs can browse telehealth NP jobs or set up job alerts. None of this is legal advice: for your own registrations, go to the DEA Diversion Control Division, your state board, or a healthcare attorney.
Frequently asked questions
Can nurse practitioners prescribe controlled substances?
Yes, when state law grants NPs that authority and the NP holds a DEA registration for the state of practice. DEA classes NPs as mid-level practitioners under 21 CFR 1300.01. State law sets the schedules, supply limits and collaboration rules; Kentucky, for example, limits most APRN Schedule II prescriptions to a 72-hour supply.
Can a psychiatric nurse practitioner prescribe medication?
Yes. A PMHNP prescribes under the state's APRN prescriptive authority and, for controlled substances, a DEA registration. Some statutes add PMHNP-specific rules: Florida exempts psychiatric medications prescribed by psychiatric nurses from its 7-day Schedule II limit, and Kentucky allows 30-day psychostimulant prescriptions only for psychiatric-certified APRNs in defined facility settings.
Can nurse practitioners prescribe Adderall and other Schedule II drugs?
It depends on the state. Amphetamine, which Adderall contains, is Schedule II under 21 CFR 1308.12, as are methylphenidate and lisdexamfetamine. State law decides whether an NP may prescribe them and for how long: Florida sets a 7-day Schedule II limit with a psychiatric exception, and Kentucky sets a 72-hour limit with a narrow 30-day psychostimulant exception for PMHNPs in defined settings.
Do nurse practitioners need their own DEA registration?
Generally, yes. DEA requires a separate registration in each state where a practitioner dispenses or prescribes controlled substances, and it registers only practitioners their state permits to prescribe. The practitioner fee is $888 for three years (21 CFR 1301.13). One exception: an NP employed by a hospital or other institution may prescribe under its registration, within that employment, if the conditions of 21 CFR 1301.22(c) are met.
Can NPs prescribe controlled substances by telehealth after December 31, 2026?
That is unsettled. The current federal flexibilities run through December 31, 2026. A final special registration rule has been under White House review since August 25, 2026, and as of October 6, 2026 no fifth extension had been published. If neither takes effect, the Ryan Haight in-person evaluation requirement applies again, with exceptions such as the buprenorphine and VA telemedicine rules.
Can nurse practitioners prescribe buprenorphine?
Yes, where state law allows it. Congress eliminated the X-waiver on December 29, 2022, so a standard DEA registration covering Schedule III is enough and patient caps are gone. DEA-registered practitioners, other than those who are solely veterinarians, must meet a one-time, eight-hour substance use disorder training requirement. Since December 31, 2025, a federal rule allows an initial six-month buprenorphine supply by telemedicine, including audio-only, after a PDMP check.
Sources
- eCFR: 21 CFR 1300.01, Definitions relating to controlled substances (up to date as of October 2, 2026)
- eCFR: 21 CFR 1301.13, Application for registration and registration fees (up to date as of October 2, 2026)
- eCFR: 21 CFR 1301.22, Exemption of agents and employees (up to date as of October 2, 2026)
- eCFR: 21 CFR 1308.12, Schedule II (up to date as of October 2, 2026)
- eCFR: 21 CFR 1308.13, Schedule III (up to date as of October 2, 2026)
- eCFR: 21 CFR 1308.14, Schedule IV (up to date as of October 2, 2026)
- DailyMed: Adderall tablet label (updated May 29, 2024)
- DEA Diversion Control Division: Exception to Separate Registration Requirements Across State Lines (DEA067) (March 25, 2020)
- DEA Diversion Control Division: Telemedicine guidance on registration in the patient's state (July 28, 2020)
- DEA: Dear Registrant letter on elimination of the DATA-Waiver (January 12, 2023)
- DEA Diversion Control Division: Dear Registrant letter on the one-time training requirement (March 27, 2023)
- Federal Register: Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, 90 FR 61301 (December 31, 2025)
- Federal Register: Expansion of Buprenorphine Treatment via Telemedicine Encounter, 90 FR 6504 (January 17, 2025; in effect December 31, 2025)
- Federal Register: Continuity of Care via Telemedicine for Veterans Affairs Patients, 90 FR 6523 (January 17, 2025; in effect December 31, 2025)
- Federal Register: Special Registrations for Telemedicine and Limited State Telemedicine Registrations, proposed rule, 90 FR 6541 (January 17, 2025)
- Reginfo.gov: OIRA regulatory review, RIN 1117-AB40 (received August 25, 2026; under review on the list dated October 5, 2026)
- Florida Legislature: Florida Statutes 464.012 (2026 Florida Statutes)
- Kentucky Legislature: KRS 314.011 (effective June 27, 2025)
- Kentucky Legislature: 201 KAR 20:057 (effective February 13, 2025)
- Missouri Revisor of Statutes: RSMo 334.104 (effective August 28, 2023)
- Missouri Revisor of Statutes: RSMo 195.030 (effective January 1, 2017)